Literature DB >> 2020918

Debrisoquine and dextromethorphan phenotyping and antidepressant treatment.

M C Perault1, S Bouquet, G Bertschy, S Vandel, R Chakroun, S Guibert, B Vandel.   

Abstract

The correlation between debrisoquine and dextromethorphan oxidation polymorphism was studied in 16 depressed in-patients. There was a close correlation between both phenotypes (r = 0.81 p less than 0.0017). During a treatment with amitriptyline during two weeks there was no significant modification of the dextromethorphan polymorphism. In the same way, the association of amitriptyline and toloxatone during two other weeks did not change this polymorphism in a significant way, even if there was a non significant shift towards higher values of the dextromethorphan metabolic ratio.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2020918

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  5 in total

Review 1.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 2.  Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.

Authors:  Jörn Lötsch; Carsten Skarke; Jürgen Liefhold; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Minor and clinically non-significant interaction between toloxatone and amitriptyline.

Authors:  S Vandel; G Bertschy; M C Perault; M Sandoz; S Bouquet; R Chakroun; S Guibert; B Vandel
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 4.  Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.

Authors:  R T Coutts
Journal:  J Psychiatry Neurosci       Date:  1994-01       Impact factor: 6.186

Review 5.  Dextromethorphan. An overview of safety issues.

Authors:  J L Bem; R Peck
Journal:  Drug Saf       Date:  1992 May-Jun       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.